Leading the Way in Life Science Technologies

GEN Exclusives

More »


More »
August 01, 2009 (Vol. 29, No. 14)

Infectious Diseases a Key MDx Market Driver

Widespread Screening Practices for All Patients Responsible for Growth in HPV and MRSA Testing

  • MRSA Diagnostics Market

    The abuse of antibiotics has led to the rise of multidrug-resistant organisms (MDROs). MRSA is the most prevalent of such MDROs with vancomycin-resistant enterococci following behind. These mutated strains are of increasing concern and pose serious public health issues.

    With fewer effective antibiotics available, infections caused by MDROs are becoming harder to treat and are associated with significantly higher rates of mortality and morbidity, longer hospital stays, and, consequently, greater healthcare costs. It is estimated that there were approximately 370,000 hospital stays for MRSA infections in 2005 in the U.S., and these stays cost an average of $14,000 versus $7,600 for all other stays. This equates to $2.4 billion in excess healthcare costs. This figure is likely to increase as MRSA screening programs continue to uncover higher infection rates.

  • Infectious Disease

    The molecular diagnostics market for CT/NG, HIV, and HCV testing are centered on diagnosis and disease monitoring, but the emerging HPV molecular diagnostics market and the MRSA molecular diagnostics market are based on widespread screening practices for all potential patients. The test volume is thus larger and  industry participants will be able to capitalize on plenty of lucrative opportunities.

    In 2007, the HPV molecular diagnostics market and the MRSA molecular diagnostics market generated $192.8 million and $80.7 million in revenues, respectively, in the U.S. In comparison, the combined market for CT/NG molecular diagnostics, HIV molecular diagnostics, and HCV molecular diagnostics totaled an estimated $600 million. The HPV and MRSA molecular diagnostics markets have the potential to grow to more than $2 billion.

Related content